|
NBN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66522351463527E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.01539895883229E-11 |
| Normal-vs-Stage2 |
2.46660000202681E-08 |
| Normal-vs-Stage3 |
1.48610013184225E-11 |
| Normal-vs-Stage4 |
1.93509985813023E-10 |
| Stage1-vs-Stage2 |
3.553200E-01 |
| Stage1-vs-Stage3 |
1.612970E-01 |
| Stage1-vs-Stage4 |
7.602100E-02 |
| Stage2-vs-Stage3 |
9.215000E-01 |
| Stage2-vs-Stage4 |
5.153200E-01 |
| Stage3-vs-Stage4 |
5.133600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.69186886722628E-12 |
| Normal-vs-AfricanAmerican |
7.81170000000442E-05 |
| Normal-vs-Asian |
4.3396000015683E-08 |
| Caucasian-vs-AfricanAmerican |
7.672200E-01 |
| Caucasian-vs-Asian |
7.720200E-01 |
| AfricanAmerican-vs-Asian |
6.426600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.23501250629488E-13 |
| Normal-vs-Female |
3.36530803224377E-12 |
| Male-vs-Female |
1.018560E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.51639997728148E-09 |
| Normal-vs-Age(41-60Yrs) |
6.26165785888588E-14 |
| Normal-vs-Age(61-80Yrs) |
1.34450006683551E-10 |
| Normal-vs-Age(81-100Yrs) |
5.502000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.081970E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.670200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.930600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.094000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.963000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.957000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.489000E-01 |
| Classical-VS-Follicular |
6.372000E-04 |
| Classical-VS-Other |
1.071630E-01 |
| Classical-VS-Normal |
1.11989972850779E-10 |
| Tall-VS-Follicular |
1.103190E-01 |
| Tall-VS-Other |
1.626200E-01 |
| Tall-VS-Normal |
1.54730999999408E-05 |
| Follicular-VS-Other |
6.659200E-01 |
| Follicular-VS-Normal |
2.97117885850184E-12 |
| Other-VS-Normal |
3.243700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.02837746599016E-13 |
| Normal-vs-N1 |
1.29440003160397E-09 |
| N0-vs-N1 |
6.035000E-01 |
|
|
